Skip to main content
. Author manuscript; available in PMC: 2015 Dec 15.
Published in final edited form as: Int J Cancer. 2014 May 12;135(12):2878–2886. doi: 10.1002/ijc.28929

Figure 3.

Figure 3

Validation of candidate proteins by IHC. A: Representative IHC staining of MX1 in stage UICC III and stage UICC II tumors. B: Boxplots for MX1, IGF1-R, and IRF2BP1. The p values calculated by the two-sample Wilcoxon test are indicated for the significant proteins. The validation cohort comprised 20 stage UICC III samples and 20 stage UICC II samples.